Percutaneous Coronary Intervention versus Coronary Artery Bypass Grafting for Non-Protected Left Main Coronary Artery

Ștefan Dan Cezar Moț1,2, Adela Mihaela Șerban1,2, Ruxandra Ștefana Beyer1

  • 1Cardiology Department, Heart Institute "N. Stăncioiu", 400001 Cluj-Napoca, Romania.

Insights

Percutaneous coronary intervention (PCI) is non-inferior to coronary artery bypass grafting (CABG) for treating left main coronary artery stenosis (LMCS). This 1-year study found similar rates of major adverse cardiovascular events (MACE) between PCI and CABG.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Cardiovascular Surgery

Background:

  • Coronary artery bypass grafting (CABG) effectively reduces major adverse cardiovascular events (MACE) in left main coronary artery stenosis (LMCS).
  • Percutaneous coronary intervention (PCI) is an emerging alternative to CABG for LMCS treatment.
  • Conflicting trial data exists regarding mortality differences between PCI and CABG for LMCS.

Purpose of the Study:

  • To determine if PCI is non-inferior to CABG in preventing MACE at 1 year in LMCS patients.
  • To compare the safety and efficacy of PCI versus CABG for LMCS revascularization.
  • To evaluate clinical outcomes at 1 year post-revascularization for LMCS.

Main Methods:

  • Prospective enrollment of 296 patients with significant LMCS.
  • Risk stratification using the Syntax II score (low, intermediate, high risk).
  • Patients underwent PCI or CABG based on guidelines or patient preference; outcomes assessed at 1 year.

Main Results:

  • No significant difference in the composite MACE endpoint at 1 year between PCI and CABG groups (37/201 vs. 35/95).
  • A trend towards higher cardiac death, repeat revascularization, and stroke was observed after CABG.
  • A trend towards higher myocardial infarction (MI) rates was observed after PCI.

Conclusions:

  • PCI with drug-eluting stents is non-inferior to CABG for LMCS at 1 year.
  • This non-inferiority holds true even for intermediate-risk patients (Syntax II score 23-32).
  • PCI offers a comparable alternative to CABG for managing LMCS regarding key adverse events.
Abstract